Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia
Conditions
Malignant Mesothelioma - Metastatic Cancer
Conditions: official terms
Hyperplasia - Lung Neoplasms - Mesothelioma - Neoplasm Metastasis
Conditions: Keywords
localized malignant mesothelioma, lung metastases, malignant pleural effusion
Study Type
Observational
Study Phase
N/A
Study Design
N/A
Intervention
Name: laboratory biomarker analysis Type: Other
Name: study of high risk factors Type: Procedure
Overall Status
Recruiting
Summary
RATIONALE: Studying levels of mesothelin and osteopontin in samples of blood from patients with mesothelioma or atypical mesothelial hyperplasia may help doctors identify biomarkers related to cancer.

PURPOSE: This research study is looking at mesothelin and osteopontin as diagnostic markers in patients with mesothelioma or atypical hyperplasia.
Detailed Description
OBJECTIVES:

Primary

- Determine if mesothelin and osteopontin in serum can serve as early markers of malignant transformation into mesothelioma.

Secondary

- Determine if there are cytological, histological, immunohistochemical, and molecular markers of precancerous disease in tissue samples.

- Determine if SV40 has a carcinogenic role.

- Determine the relationship between the serum concentration of mesothelin and/or osteopontin and the expression of other markers and with clinical progression.

OUTLINE: This is a multicenter study.

Levels of mesothelin and osteopontin in serum (and pleural fluid, if effusion is present) are measured at baseline and 3, 6, 12, and 24 months. Patients with mesothelioma, reactional lesions, or adenocarcinoma undergo tomodensitometry (TDM) at baseline, 3, 6, and 12 months. Patients with pleural plaques only undergo TDM at 12 months.

Patients are followed for 5 years.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Both
Criteria: DISEASE CHARACTERISTICS:

Inclusion criteria:

- Diagnosis of mesothelial hyperplasia and meeting 1 of the following criteria:

- Confirmed prior exposure to asbestos and presence of pleural effusion and meets 1 of the following diagnostic criteria:

- Mesothelioma

- Mesothelial hyperplasia of unspecified malignancy

- Reactional inflammatory hyperplasia

- No asbestos exposure but pleural effusion with pleural malignant mesothelioma or pulmonary metastasis

- Prior exposure to asbestos, no pleural effusion, and asymptomatic (pleural plaques present)

- No prior exposure to asbestos but with benign pleural effusion

- Tissue obtained by pleuroscopy, surgical biopsy, or video-thoracoscopy available

- Paraffin-embedded and frozen tissue available

Exclusion criteria:

- Solitary fibrous tumor

- Diffuse pleural fibrosis

- Purulent pleurisy

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- No prior chemotherapy or radiotherapy
Location
CHU de Caen
Caen, France
Status: Recruiting
Contact: Francoise Galateau-Salle - 33-231-064-923
Start Date
April 2007
Sponsors
University Hospital, Caen
Source
National Cancer Institute (NCI)
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page